IO Biotech, Inc.

NASDAQ:IOBT

0.83 (USD) • At close January 14, 2025
Bedrijfsnaam IO Biotech, Inc.
Symbool IOBT
Munteenheid USD
Prijs 0.829
Beurswaarde 54,615,274
Dividendpercentage 0%
52-weken bereik 0.66 - 1.95
Industrie Biotechnology
Sector Healthcare
CEO Dr. Mai-Britt Zocca Ph.D.
Website https://www.iobiotech.com

An error occurred while fetching data.

Over IO Biotech, Inc.

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as

Vergelijkbare Aandelen

Assertio Holdings, Inc. logo

Assertio Holdings, Inc.

ASRT

0.797 USD

Ikena Oncology, Inc. logo

Ikena Oncology, Inc.

IKNA

1.51 USD

DarioHealth Corp. logo

DarioHealth Corp.

DRIO

0.692 USD

AVITA Medical, Inc. logo

AVITA Medical, Inc.

RCEL

9.96 USD

Sol-Gel Technologies Ltd. logo

Sol-Gel Technologies Ltd.

SLGL

1.26 USD

Citius Pharmaceuticals, Inc. logo

Citius Pharmaceuticals, Inc.

CTXR

3.56 USD

Ovid Therapeutics Inc. logo

Ovid Therapeutics Inc.

OVID

0.757 USD

ProPhase Labs, Inc. logo

ProPhase Labs, Inc.

PRPH

0.606 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)